Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,investments,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,EGRX,139124000.0,13119000,14288000,,1340000,,-421000,19879000,30394000,-3773000,-3773000,,-422000,,,,1761000,41249000,45022000,10855000,5113000,,-421000,-421000,12211000.0,312323000.0,68890000.0,191078000.0,259968000.0,17000.0,5592000.0,84068000.0,39743000.0,-205330000.0,23958000.0,105229000.0,41973000.0,14278000.0,8000000.0,2270000.0,163986000.0,17800000.0,44868000.0,23253000.0,6862000.0,12559000.0,6291000.0,-5384000.0,-2000000.0,-3020000.0,-5591000.0,1963000.0,2074000.0,-2983000.0,10478000.0,1148000.0,-5000000.0,1213000.0,5810000.0,1910000.0,-384000.0,,122013000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.924999,0.43654054,36.48 - 53.78,-1.375,-0.025567126,36.48,53.78,1620649800,1620649800,1620649800,49.392082,1.061,4.16,3.12,-1.8081323,52.37 - 53.78,53.37,52.47,52.83,9,9,finmb_3474216,NasdaqGM,"Eagle Pharmaceuticals, Inc.",USD,120275,86750,16.796474,14.536,47.9175,4.487499,0.09365053,43.84667,8.558331,0.1951877,687501184,12.597356,3.605187,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eagle Pharmaceuticals, Inc.",52.405,1630507845,-0.96500015,53.78,53.78,52.37,19524,0.75,,,53.78,36.48,47.92,43.85,120.28k,86.75k,13.12M,,11.55M,12.41%,95.32%,955.77k,5.99,12.13%,7.29%,1.06M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",7.89%,12.37%,4.55%,7.74%,183.03M,13.73,-10.40%,142.34M,26.16M,14.44M,1.06,,105.23M,8.03,36.06M,18.87,3.91,14.54,56.82M,60.23M,Value,07677,Healthcare,106,9,8,"Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.",Woodcliff Lake,201 326 5300,NJ,8,1609372800,1625097600,7,United States,http://www.eagleus.com,86400,8,50 Tice Boulevard,Drug Manufacturers—Specialty & Generic,Suite 315
t-1,EGRX,133351000.0,13119000,9395000,,11387000,,8057000,18187000,37375000,9793000,9793000,,-413000,,,,3330000,49916000,40123000,12541000,1594000,,8057000,8057000,12917000.0,305403000.0,67179000.0,186011000.0,253190000.0,17000.0,2265000.0,84489000.0,39743000.0,-203898000.0,32388000.0,103155000.0,38085000.0,15180000.0,8000000.0,2077000.0,166065000.0,,51117000.0,25135000.0,8075000.0,6268000.0,-6800000.0,-170000.0,-2000000.0,-6116000.0,13167000.0,3099000.0,13474000.0,-7215000.0,19760000.0,1131000.0,-5000000.0,-1489000.0,1082000.0,4494000.0,-170000.0,,127980000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.924999,0.43654054,36.48 - 53.78,-1.375,-0.025567126,36.48,53.78,1620649800,1620649800,1620649800,49.392082,1.061,4.16,3.12,-1.8081323,52.37 - 53.78,53.37,52.47,52.83,9,9,finmb_3474216,NasdaqGM,"Eagle Pharmaceuticals, Inc.",USD,120275,86750,16.796474,14.536,47.9175,4.487499,0.09365053,43.84667,8.558331,0.1951877,687501184,12.597356,3.605187,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eagle Pharmaceuticals, Inc.",52.405,1630507845,-0.96500015,53.78,53.78,52.37,19524,0.75,,,53.78,36.48,47.92,43.85,120.28k,86.75k,13.12M,,11.55M,12.41%,95.32%,955.77k,5.99,12.13%,7.29%,1.06M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",7.89%,12.37%,4.55%,7.74%,183.03M,13.73,-10.40%,142.34M,26.16M,14.44M,1.06,,105.23M,8.03,36.06M,18.87,3.91,14.54,56.82M,60.23M,Value,07677,Healthcare,106,9,8,"Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.",Woodcliff Lake,201 326 5300,NJ,8,1609372800,1625097600,7,United States,http://www.eagleus.com,86400,8,50 Tice Boulevard,Drug Manufacturers—Specialty & Generic,Suite 315
t-2,EGRX,119460000.0,13119000,4828000,,8925000,,7059000,17697000,37942000,15417000,15417000,,-489000,,,,1866000,49928000,34511000,11986000,-6492000,,7059000,7059000,13584000.0,296198000.0,75374000.0,172787000.0,248161000.0,17000.0,8208000.0,76432000.0,39743000.0,-199860000.0,25337000.0,89681000.0,45513000.0,15340000.0,8000000.0,5701000.0,163796000.0,,57199000.0,27017000.0,6586000.0,13068000.0,-640000.0,-201000.0,-1000000.0,-23958000.0,-8184000.0,42000.0,-18532000.0,-23000000.0,5627000.0,1371000.0,-17500000.0,1305000.0,-5418000.0,10016000.0,-201000.0,17500000.0,118283000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.924999,0.43654054,36.48 - 53.78,-1.375,-0.025567126,36.48,53.78,1620649800,1620649800,1620649800,49.392082,1.061,4.16,3.12,-1.8081323,52.37 - 53.78,53.37,52.47,52.83,9,9,finmb_3474216,NasdaqGM,"Eagle Pharmaceuticals, Inc.",USD,120275,86750,16.796474,14.536,47.9175,4.487499,0.09365053,43.84667,8.558331,0.1951877,687501184,12.597356,3.605187,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eagle Pharmaceuticals, Inc.",52.405,1630507845,-0.96500015,53.78,53.78,52.37,19524,0.75,,,53.78,36.48,47.92,43.85,120.28k,86.75k,13.12M,,11.55M,12.41%,95.32%,955.77k,5.99,12.13%,7.29%,1.06M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",7.89%,12.37%,4.55%,7.74%,183.03M,13.73,-10.40%,142.34M,26.16M,14.44M,1.06,,105.23M,8.03,36.06M,18.87,3.91,14.54,56.82M,60.23M,Value,07677,Healthcare,106,9,8,"Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.",Woodcliff Lake,201 326 5300,NJ,8,1609372800,1625097600,7,United States,http://www.eagleus.com,86400,8,50 Tice Boulevard,Drug Manufacturers—Specialty & Generic,Suite 315
t-3,EGRX,129971000.0,13119000,7135000,,5373000,,-256000,17959000,28803000,3709000,3709000,,-786000,,,,5629000,41938000,38229000,13135000,1664000,,-256000,-256000,14250000.0,291434000.0,72746000.0,183964000.0,256710000.0,17000.0,4529000.0,69373000.0,39743000.0,-176860000.0,28076000.0,108213000.0,40486000.0,14585000.0,7000000.0,6205000.0,168436000.0,,46781000.0,28899000.0,7891000.0,13708000.0,3952000.0,96000.0,-111000000.0,-114851000.0,4644000.0,183000.0,-93803000.0,-4034000.0,20952000.0,1126000.0,-17500000.0,543000.0,7710000.0,3115000.0,96000.0,17500000.0,127950000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.924999,0.43654054,36.48 - 53.78,-1.375,-0.025567126,36.48,53.78,1620649800,1620649800,1620649800,49.392082,1.061,4.16,3.12,-1.8081323,52.37 - 53.78,53.37,52.47,52.83,9,9,finmb_3474216,NasdaqGM,"Eagle Pharmaceuticals, Inc.",USD,120275,86750,16.796474,14.536,47.9175,4.487499,0.09365053,43.84667,8.558331,0.1951877,687501184,12.597356,3.605187,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eagle Pharmaceuticals, Inc.",52.405,1630507845,-0.96500015,53.78,53.78,52.37,19524,0.75,,,53.78,36.48,47.92,43.85,120.28k,86.75k,13.12M,,11.55M,12.41%,95.32%,955.77k,5.99,12.13%,7.29%,1.06M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",7.89%,12.37%,4.55%,7.74%,183.03M,13.73,-10.40%,142.34M,26.16M,14.44M,1.06,,105.23M,8.03,36.06M,18.87,3.91,14.54,56.82M,60.23M,Value,07677,Healthcare,106,9,8,"Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.",Woodcliff Lake,201 326 5300,NJ,8,1609372800,1625097600,7,United States,http://www.eagleus.com,86400,8,50 Tice Boulevard,Drug Manufacturers—Specialty & Generic,Suite 315
